Loading...
•
Jun 30, 2022
Lianbio-Adr Q2 2022 Earnings Report
LianBio-Adr's financial performance was reported for Q2 2022 and a corporate update was provided.
Key Takeaways
LianBio reported a net loss of $42.4 million for the second quarter of 2022, with research and development expenses at $28.6 million and general and administrative expenses at $14.6 million. The company's cash balance at the end of the quarter was $349.4 million, expected to fund operations into the second half of 2024. Key milestones included completing enrollment in the China Phase 3 trial of mavacamten and submitting NDAs for mavacamten in Singapore and infigratinib in Hong Kong.
Completed enrollment in China Phase 3 trial of mavacamten with topline data expected mid-2023.
Submitted mavacamten New Drug Application (NDA) in Singapore.
Submitted infigratinib NDA in Hong Kong.
Cash balance of $349.4 million at the end of second quarter 2022 with runway into the second half of 2024.
Forward Guidance
LianBio anticipates several key milestones in 2022 and 2023, focusing on advancing its clinical programs and preparing for potential commercialization.
Positive Outlook
- Topline data from the Phase 3 EXPLORER-CN trial of mavacamten is expected in mid-2023.
- A Phase 3 study in Chinese patients with Demodex blepharitis for TP-03 is expected to begin in the second half of 2022.
- Dosing patients in Nanobiotix’s global Phase 3 NANORAY-312 clinical trial of NBTXR3 is expected to begin in the second half of 2022.
- A Phase 1 monotherapy clinical trial of BBP-398 in advanced solid tumors is expected to begin in the fourth quarter of 2022.
- A Phase 1 clinical trial of BBP-398 in combination with an EGFR-inhibitor in non-small cell lung cancer is expected to begin in the first half of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...